How to buy AlloVir (ALVR) stock

AlloVir, Inc is a biotechnology business based in the US. AlloVir shares (ALVR) are listed on the NASDAQ and all prices are listed in US Dollars. AlloVir employs 74 staff and has a market cap (total outstanding shares value) of 0.00.

AlloVir stock price (NASDAQ: ALVR)

Use our graph to track the performance of ALVR stocks over time.

AlloVir shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$23.44
52-week range	$16.66 - $48.96
50-day moving average	$20.30
200-day moving average	$28.28
Wall St. target price	$49.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy AlloVir shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy AlloVir stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of AlloVir, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AlloVir price performance over time

Historical closes compared with the close of $23.44 from 2021-05-28

1 week (2021-07-15)	N/A
1 month (2021-06-25)	10.72%
3 months (2021-04-26)	-0.34%
6 months (2021-01-22)	N/A

1 year (2020-07-22)	N/A
2 years (2019-07-22)	N/A
3 years (2018-07-22)	N/A
5 years (2016-07-22)	N/A

AlloVir financials

Gross profit TTM	$165,000
Return on assets TTM	-24.05%
Return on equity TTM	-41.21%
Profit margin	0%
Book value	$5.36
Market capitalisation	$1.1 billion

TTM: trailing 12 months

Shorting AlloVir shares

There are currently 4.1 million AlloVir shares held short by investors – that's known as AlloVir's "short interest". This figure is 4.9% down from 4.3 million last month.

There are a few different ways that this level of interest in shorting AlloVir shares can be evaluated.

AlloVir's "short interest ratio" (SIR)

AlloVir's "short interest ratio" (SIR) is the quantity of AlloVir shares currently shorted divided by the average quantity of AlloVir shares traded daily (recently around 284828.8981289). AlloVir's SIR currently stands at 14.43. In other words for every 100,000 AlloVir shares traded daily on the market, roughly 14430 shares are currently held short.

However AlloVir's short interest can also be evaluated against the total number of AlloVir shares, or, against the total number of tradable AlloVir shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AlloVir's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 AlloVir shares in existence, roughly 70 shares are currently held short) or 0.1499% of the tradable shares (for every 100,000 tradable AlloVir shares, roughly 150 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against AlloVir.

Find out more about how you can short AlloVir stock.

AlloVir share dividends

We're not expecting AlloVir to pay a dividend over the next 12 months.

AlloVir overview

Allovir, Inc. , a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019.

Frequently asked questions

What percentage of AlloVir is owned by insiders or institutions?
Currently 51.412% of AlloVir shares are held by insiders and 41.609% by institutions. How many people work for AlloVir?
Latest data suggests 74 work at AlloVir. When does the fiscal year end for AlloVir?
AlloVir's fiscal year ends in December. Where is AlloVir based?
AlloVir's address is: 139 Main Street, Cambridge, MA, United States, 02142 What is AlloVir's ISIN number?
AlloVir's international securities identification number is: US0198181036